Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.013
Sell
RSI(14)
47.725
Neutral
STOCH(KDJ)(9,3,3)
25.137
Neutral
ATR(14)
1.584
Low Volatility
CCI(14)
-51.016
Neutral
Williams %R
52.608
Neutral
TRIX(12,20)
-0.137
Sell
StochRSI(14)
66.421
Buy
Xenon Pharmaceuticals Inc
XENE41.380USD
+0.990+2.45%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
3.19BMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Xenon Pharmaceuticals Inc
Currency: USD Updated: 2026-02-06Key Insights
Xenon Pharmaceuticals Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 35 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 55.03.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Xenon Pharmaceuticals Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Xenon Pharmaceuticals Inc Highlights
StrengthsRisks
Xenon Pharmaceuticals Inc. is a Canada-based neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing therapeutics to improve the lives of people living with neurological and psychiatric disorders. The Company is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the advanced, clinically validated potassium channel modulator in late-stage clinical development for the treatment of multiple indications that include epilepsy, including focal onset seizures (FOS), and primary generalized tonic-clonic seizures (PGTCS), as well as neuropsychiatric disorders including major depressive disorder (MDD), and bipolar depression (BPD). The Company is evaluating multiple therapeutic candidates targeting Kv7, Nav1.7, and Nav1.1 across various indications.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Overvalued
The company’s latest PE is -10.65, at a high 3-year percentile range.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 473.00 shares of this stock.
Analyst Rating
Based on
20
analysts
Buy
Current Rating
55.029
Target Price
+33.73%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-02-06The current financial score of Xenon Pharmaceuticals Inc is 6.48, ranking 250 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.
Score
Financials
8.84
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.53
Operational Efficiency
2.57
Growth Potential
6.35
Shareholder Returns
7.13
Xenon Pharmaceuticals Inc's Company Valuation
Currency: USD Updated: 2026-02-06The current valuation score of Xenon Pharmaceuticals Inc is 6.67, ranking 240 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -10.65, which is -19.72% below the recent high of -8.55 and -83.64% above the recent low of -19.55.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 35/392
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-02-06The current earnings forecast score of Xenon Pharmaceuticals Inc is 8.80, ranking 48 out of 392 in the Biotechnology & Medical Research industry. The average price target is 55.00, with a high of 65.00 and a low of 44.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
20
analysts
Buy
Current Rating
55.029
Target Price
+33.73%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
542
Total
6
Median
6
Average
Company name
Ratings
Analysts
Xenon Pharmaceuticals Inc
XENE
20
CRISPR Therapeutics AG
CRSP
29
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Intellia Therapeutics Inc
NTLA
24
Beigene Ltd
ONC
24
1
2
3
...
109
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-02-06The current price momentum score of Xenon Pharmaceuticals Inc is 6.97, ranking 127 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 43.66 and the support level at 39.19, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
41.298
Buy
MA10
41.580
Sell
MA20
41.417
Sell
MA50
42.846
Sell
MA100
41.389
Sell
MA200
37.609
Buy
Institutional Confidence
Currency: USD Updated: 2026-02-06The current institutional shareholding score of Xenon Pharmaceuticals Inc is 10.00, ranking 1 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 116.66%, representing a quarter-over-quarter increase of 3.77%. The largest institutional shareholder is The Vanguard, holding a total of 646.55K shares, representing 0.84% of shares outstanding, with 99.40% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-02-06The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Xenon Pharmaceuticals Inc is 7.87, ranking 7 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.93. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
0.92
VaR
+4.34%
240-Day Maximum Drawdown
+27.80%
240-Day Volatility
+48.92%
Return
Best Daily Return
60 days
+4.49%
120 days
+5.17%
5 years
+101.92%
Worst Daily Return
60 days
-6.07%
120 days
-6.07%
5 years
-17.43%
Sharpe Ratio
60 days
+1.15
120 days
+0.72
5 years
+0.52
Risk Assessment
Maximum Drawdown
240 days
+27.80%
3 years
+43.59%
5 years
+43.59%
Return-to-Drawdown Ratio
240 days
+0.28
3 years
+0.14
5 years
+0.58
Skewness
240 days
-0.76
3 years
+0.19
5 years
+12.84
Volatility
Realised Volatility
240 days
+48.92%
5 years
+58.31%
Standardised True Range
240 days
+3.72%
5 years
+3.80%
Downside Risk-Adjusted Return
120 days
+130.80%
240 days
+130.80%
Maximum Daily Upside Volatility
60 days
+25.55%
Maximum Daily Downside Volatility
60 days
+23.10%
Liquidity
Average Turnover Rate
60 days
+1.42%
120 days
+1.36%
5 years
--
Turnover Deviation
20 days
+57.99%
60 days
+77.33%
120 days
+70.06%
Peer Comparison
Biotechnology & Medical Research
Xenon Pharmaceuticals Inc
XENE
7.56 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.60 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.53 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ionis Pharmaceuticals Inc
IONS
8.38 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.37 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.17 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
